The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of bridging therapy (BT) on lisocabtagene maraleucel (liso-cel) treatment in patients (pt) with R/R follicular lymphoma (FL).
 
Juan Luis Reguera
Consulting or Advisory Role - BMS GmbH & Co. KG; Janssen Oncology; Novartis
Speakers' Bureau - Amgen; Janssen; Kite/Gilead; Sanofi
Travel, Accommodations, Expenses - Kite/Gilead
 
Alejandro Martin Garcia-Sancho
Honoraria - Celgene; Eusa Pharma; Gilead Sciences; Janssen-Cilag; Novartis; Roche; Takeda
Consulting or Advisory Role - Abbvie; ADC Therapeutics; BMS; Gilead Sciences; Ideogen; Incyte; Kyowa Hakko Kirin; Lilly; Miltenyi Biomedicine; Novartis; Roche
Expert Testimony - Gilead Sciences
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen Oncology; Kern Pharma; Roche
 
John Kuruvilla
Honoraria - Abbvie; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Karyopharm Therapeutics; Merck; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Gilead Sciences; Karyopharm Therapeutics; Merck; Monte Rosa Therapeutics; Roche; Seagen
Research Funding - AstraZeneca; Merck; Roche
Other Relationship - Karyopharm Therapeutics
 
Koji Izutsu
Honoraria - Abbvie; Abbvie; Allergan; AstraZeneca; Bayer; Bristol Myers Squibb; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Fujifilm; HUYA Bioscience International; Janssen; Janssen; Kyowa Kirin; Lilly; Meiji Seika Kaisha; Meiji Seika Kaisha; MSD; MSD; Mundipharma; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Pfizer; SymBio Pharmaceuticals; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; Bayer; Bristol Myers Squibb; Celgene; Genmab; Kyowa Kirin; Mitsubishi Tanabe Pharma; Nippon Shinyaku; Ono Pharmaceutical
Research Funding - Chugai Pharma; Eisai
 
Anna Maria Barbui
Consulting or Advisory Role - Roche
Speakers' Bureau - Incyte
Travel, Accommodations, Expenses - Gilead Sciences
 
Borchmann Peter
Honoraria - Abbvie; Bristol-Myers Squibb; Celgene; Gilead Sciences; Incyte; Miltenyi Biotec; MSD; Novartis; Roche; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Gilead Sciences; Miltenyi Biotec; Novartis; Roche; Takeda
Research Funding - Incyte (Inst); MSD (Inst); Novartis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Kite/Gilead; Roche; Takeda
 
Stephan Mielke
Leadership - SWECARNET: Founder/Leadership (Inst)
Speakers' Bureau - Celgene/Bristol-Myers Squibb (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Kite/Gilead (Inst)
Other Relationship - Immunicum/Mendes: Data safety monitoring board (Inst); Miltenyi: Data safety monitoring board (Inst)
 
Maria Lia Palomba
Stock and Other Ownership Interests - Notch Therapeutics (I); Pluto Immunotherapeutics (I); Seres Therapeutics (I)
Honoraria - ceramedix (I); Frazier Healthcare Partners (I); Garuda Therapeutics (I); GlaxoSmithKline (I); Lygenesis (I); Nektar (I); Notch Therapeutics (I); Pluto Immunotherapeutics (I); Rheos Medicines (I); Seres Therapeutics (I); thymofox (I)
Consulting or Advisory Role - BeiGene; bristol m; Cellectar; MustangBio; Seres Therapeutics (I); Synthekine
Research Funding - Seres Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Intellectual Property Rights (I); Juno intellectual property rights (Inst)
 
Guillaume Cartron
Honoraria - Abbvie; BMS; Gilead Sciences; Janssen; Novartis; Roche
Consulting or Advisory Role - BMS; Mabqi; MedxCell; Roche
Travel, Accommodations, Expenses - Gilead Sciences; Roche
 
Hervé Ghesquieres
Honoraria - Abbvie; Gilead Sciences; Roche
Consulting or Advisory Role - Gilead Sciences; Roche
Travel, Accommodations, Expenses - Abbvie; Pierre Fabre
 
Hideki Goto
Research Funding - Bristol-Myers Squibb (Inst); Kyowa Kirin (Inst); Sanofi (Inst); SymBio Pharmaceuticals (Inst)
 
Indumathy Varadarajan
Honoraria - Advisory board for Rezurock; Novartis
 
Thalia Farazi
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Bristol Myers Squibb
 
Grace Shih Hui Kao
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Min Vedal
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Rina Nishii
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jessica Papuga
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Franck Morschhauser
Honoraria - Chugai/Roche; Roche/Genentech; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genmab; Gilead Sciences; Modex therapeutics; Novartis; Roche/Genentech